Project Grant R44CA278186
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
This $962,560 Project Grant (R01CA285369) awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries. The key products and services to be delivered under this 5-year award include: Modifying the IRISTM prototype to incorporate an endocervical probe and...
Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
The National Cancer Institute (NCI) awarded a $957,152 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to GE Medical Systems Information Technologies, Inc. (GE Healthcare Technology & Innovation Center) to develop an automated, portable point-of-care telecytology platform for oral cancer screening in India. The platform will enable immediate diagnosis of suspicious oral lesions through AI-powered analysis of brush biopsy cytology samples,...
The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, will fund the development and pilot testing of the Integrated Cancer Awareness Network (ICAN), an innovative mHealth platform. ICAN will provide cancer risk, symptom, and screening education to...
This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop a low-cost, portable Mini-Reflectance Confocal Microscope (Mini-RCM) device to aid in skin cancer diagnosis and treatment. The $400,000 award, effective February 1, 2025 through January 31, 2026, will fund the development of the Mini-RCM device (Aim 1) and in vivo evaluation of its performance for imaging skin lesions (Aim 2). The...
This SBIR Phase I Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $305,000 to Glow Therapeutics Inc., a small minority-owned business, to advance the development of a novel light-activatable nanoplatform for the targeted co-delivery of photodynamic therapy (PDT) and chemotherapy to treat peritoneal metastasis. The nanoplatform is designed to selectively target and eliminate cancer cells that could not be removed by...